Search results
Gilead's Chronic Hepatitis Delta Infection Treatment Shows Sustained Efficacy, Safety Profile At Two...
Benzinga via Yahoo Finance· 10 months agoGilead Sciences Inc (NASDAQ: GILD) announced Week 96 results from the MYR301 Phase 3 clinical trial...
GSK/Pfizer-Backed ViiV Healthcare's HIV Treatment At Par With Gilead's: Study Shows
Benzinga via Yahoo Finance· 1 year agoViiV Healthcare, majority-owned by GSK Plc (NYSE: GSK), Pfizer Inc (NYSE: PFE), and Shionogi...
Gilead Sciences (GILD) Announces Positive HDV Treatment Data
Zacks via Yahoo Finance· 10 months agoGilead Sciences, Inc. (GILD) announces data on Hepcludex that reinforces the potential of...
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q1 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 1 year agoEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q1 2023 Earnings Call Transcript February 7, 2023...
Atea Pharma (AVIR) Gains on Upbeat Initial Data From HCV Study
Zacks via Yahoo Finance· 4 months agoAtea Pharma (AVIR) gains 11% after reporting positive initial results from the first 52 patients in...
Q4 2023 Vir Biotechnology Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 2 months agoParticipants Sasha Damouni Ellis; Executive Vice President and Chief Corporate Affairs Officer; Vir Biotechnology Inc Marianne De Backer; Chief Executive Officer, Director; Vir Biotechnology ...
Q3 2023 Enanta Pharmaceuticals Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 9 months agoParticipants Jay R. Luly; President, CEO & Director; Enanta Pharmaceuticals, Inc. Jennifer Viera; Senior Director of IR & Corporate Communications; Enanta Pharmaceuticals, Inc. Paul J. Mellett ...
Biotech Stock Roundup: BIIB, GSK's Q2 Earnings, KOD Faces Setback & More
Zacks via Yahoo Finance· 9 months agoIt was a busy week for the biotech sector, with a focus on earnings and important regulatory and...
